Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach

Yizhe Mao; Tuba N. Gide; Nurudeen A. Adegoke; Camelia Quek; Nigel Maher; Alison J. Potter; Ellis Patrick; Robyn P.M. Saw; John F. Thompson; Andrew J. Spillane; Kerwin F. Shannon; Matteo S. Carlino; Serigne Lo; Alexander M. Menzies; Inês Pires da Silva; Georgina V. Long; Richard A Scolyer; James S. Wilmott

doi:10.1186/s12967-023-04092-9

Related publications

Article2023

Abstract 5479: A six-protein signature predicts response and survival in patients with advanced cutaneous melanoma treated with immunotherapy

Srikanth S. Manda, Adel T. Aref, Erin K. Sykes, Steven G. Williams, Jennifer M.S. Koh, Erin M. Humphries, Daniel Bucio-Noble, Daniela Lee-Smith, Natasha Lucas, Dylan Xavier, Alexander M. Menzies, Inês Da Silva, Felicity Newell, Rosemary L. Balleine, Peter G. Hains, Graham J. Mann, Philip Robinson, Georgina V. Long, James S. Wilmott, Qing Zhong, Richard A Scolyer, Roger R. Reddel

Article2025

Abstract 6360: A tumor agnostic composite gene expression signature identifies three groups of patients treated with immune checkpoint blockade with distinct clinical outcome

Mehdi Lamkhioued, Guillaume Robert-Siegwald, Roxane M. Pommier, David M. Tricoli, Camille Brodin, Valéry Attignon, Nicolas Gadot, Séverine Tabone‐Eglinger, F.N. Jerome, Aurélie Swalduz, Isabelle Ray‐Coquard, Eve‐Marie Neidhardt, Clélia Coutzac, Loïc Verlingue, Olivier Trédan, Jean Yves Blay, Christophe Caux, Alain Viari, Nicolas Poirier, Aurore Morello, Isabelle Girault,

Article2023

Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.

Minke W. Lucas, Petros Dimitriadis, Irene L. M. Reijers, Alexander M. Menzies, Elisa A. Rozeman, Judith M. Versluis, Alexander C. Huang, Sten Cornelissen, Annegien Broeks, Richard A Scolyer, Tara C. Mitchell, Georgina V. Long, Christian U. Blank

Article2024

Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

Sara Cabrero‐de las Heras, Xavier Hernández‐Yagüe, Andrea González, Ferrán Losa, Gemma Soler, Cristina Bugés, Iosune Baraibar, Anna Esteve, Miguel Ángel Pardo-Cea, Anne Hansen Ree, Neus Martínez-Bosch, Maria Nieva, Eva Musulen, Sebastian Meltzer, Tania Lobato, Carla Vendrell-Ayats, Cristina Queralt, Pilar Navarro, Clara Montagut, Ferran Grau‐Leal, David Camacho, Raquel Legido,

Article2023

Abstract 4621: Distinct spatial and molecular maps in the tumour microenvironment of resistant melanoma patients treated with checkpoint inhibitor immunotherapy

Camelia Quek, Aditya Pratapa, Inês Pires da Silva, Ghamdan Al‐Eryani, Aaron T. Mayer, Nenad Bartoniček, Kate Harvey, Oliver Braubach, Robyn P.M. Saw, Jonathan R. Stretch, Kerwin F. Shannon, Alexander M. Menzies, Richard A Scolyer, Georgina V. Long, Alexander Swarbrick, James S. Wilmott

Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach

Abstract

Discussion(0)

Related publications

Abstract 5479: A six-protein signature predicts response and survival in patients with advanced cutaneous melanoma treated with immunotherapy

Abstract 6360: A tumor agnostic composite gene expression signature identifies three groups of patients treated with immune checkpoint blockade with distinct clinical outcome

Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.

Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

Abstract 4621: Distinct spatial and molecular maps in the tumour microenvironment of resistant melanoma patients treated with checkpoint inhibitor immunotherapy